NCT02452385 is a Phase 1 clinical trial of CM082 tablet in Age-Related Macular Degeneration, sponsored by AnewPharma.

Who is sponsoring NCT02452385?

NCT02452385 is sponsored by AnewPharma.

What drugs are being tested in NCT02452385?

Interventions in NCT02452385: CM082 tablet.

What condition does NCT02452385 study?

NCT02452385 studies Age-Related Macular Degeneration.

Is NCT02452385 still recruiting?

NCT02452385 is currently suspended. Last updated 8 January 2020.

Last reviewed 2020-01-08 · How we verify

NCT02452385

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of CM082 in Patients With wAMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy

Suspended Phase 1 Last updated 8 January 2020

What this trial tests

Phase 1 trial testing CM082 tablet in Age-Related Macular Degeneration in 56 participants. Suspended.

Timeline

1 March 2015

Primary endpoint
1 June 2020

1 June 2020

Quick facts

Lead sponsor	AnewPharma
Phase	Phase 1
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	56
Start date	1 March 2015
Primary completion	1 June 2020
Estimated completion	1 June 2020
Sites	6 locations across China

Drugs / interventions tested

CM082 tablet

Conditions studied

Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →

Sponsor

AnewPharma — full company profile →

Who can join

50 and older, any sex, with Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: six months
Incidence of the adverse event after treatment

Sponsor's own description

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats.
Ren C, Shi H, Jiang J, Liu Q, et al · · 2017 · cited 9× · PMID 29201457 · DOI 10.1155/2017/6145651
Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study.
Gao Y, Lu F, Li X, Dai H, et al · · 2023 · cited 4× · PMID 37041349 · DOI 10.1038/s41433-023-02496-x

Verify or expand the search:

Other recruiting trials for Age-Related Macular Degeneration

Currently open trials in the same condition.

NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting

Other AnewPharma trials

Trials by the same sponsor.

NCT04434326 — The Absorption, Metabolism and Excretion of [14C]CM082 in Human · Phase 1 · completed
NCT04328506 — Bioequivalency Study of CM082 Tablet in Healthy Volunteers · Phase 1 · completed
NCT04126668 — A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers · Phase 1 · completed
NCT04222842 — CM082 in Patients With Myopic Choroidal Neovascularization (CNV) · Phase 1 · suspended
NCT03904719 — CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02452385 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AnewPharma
Last refreshed: 8 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02452385.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing